Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ011133 (Lemzoparlimab) plus Toripalimab in Advanced Solid Tumors
NCT05148533Phase 2Terminated
- Sponsor
- TJ Biopharma
- Start
- Dec 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lemzoparlimab in solid tumor (advanced stage), melanoma, gastric cancer (GC) and 1 more, sponsored by TJ Biopharma. Primary endpoints: Incidence and Severity of Adverse Events at 1 year and Objective Response Rate at 1 year. Started Dec 2021; status: terminated.
02
Drugs
lemzoparlimab
03
Conditions
solid tumor (advanced stage)melanomagastric cancer (GC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05148533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148533.